Search for pathogenesis and novel therapeutics of acquired myelodysplastic syndromes using reprogramming technology
Project/Area Number |
26860727
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Hematology
|
Research Institution | Kyoto University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 骨髄異形成症候群 / 血液分化異常 / リプログラミング / iPS細胞 / 病態解明 / 新規治療薬 / MDS / 造血前駆細胞 |
Outline of Final Research Achievements |
We successfully generated multiple iPS cell lines from MDS clones (MDS-iPSC lines) of several MDS patients with abnormal karyotypes. We assessed hematopoietic differentiation potential of MDS-iPSC lines and isogenic normal T-iPSC lines. Hematopoietic colony formation in methylcellulose culture and further differentiation in erythroid and neutrophil culture were severely impaired in all tested MDS-iPSC lines. Next, we performed microarray analysis in hematopoietic progenitor cells re-induced from MDS-iPSC lines and isogenic normal iPSC lines, identifying MDS-specific expression changes. Finally, we performed whole-exome analysis to find that some of the somatic mutations detected in bulk cells of this MDS patient are shared in MDS-iPSC lines but not in isogenic normal iPSC lines.
|
Report
(3 results)
Research Products
(6 results)